These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27453480)

  • 1. Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity.
    Smith BK; Martin AD; Lawson LA; Vernot V; Marcus J; Islam S; Shafi N; Corti M; Collins SW; Byrne BJ
    Exp Neurol; 2017 Jan; 287(Pt 2):216-224. PubMed ID: 27453480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.
    Smith BK; Collins SW; Conlon TJ; Mah CS; Lawson LA; Martin AD; Fuller DD; Cleaver BD; Clément N; Phillips D; Islam S; Dobjia N; Byrne BJ
    Hum Gene Ther; 2013 Jun; 24(6):630-40. PubMed ID: 23570273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.
    Corti M; Liberati C; Smith BK; Lawson LA; Tuna IS; Conlon TJ; Coleman KE; Islam S; Herzog RW; Fuller DD; Collins SW; Byrne BJ
    Hum Gene Ther Clin Dev; 2017 Dec; 28(4):208-218. PubMed ID: 29160099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.
    Falk DJ; Mah CS; Soustek MS; Lee KZ; Elmallah MK; Cloutier DA; Fuller DD; Byrne BJ
    Mol Ther; 2013 Sep; 21(9):1661-7. PubMed ID: 23732990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diaphragm Pacing as a Rehabilitative Tool for Patients With Pompe Disease Who Are Ventilator-Dependent: Case Series.
    Smith BK; Fuller DD; Martin AD; Lottenberg L; Islam S; Lawson LA; Onders RP; Byrne BJ
    Phys Ther; 2016 May; 96(5):696-703. PubMed ID: 26893511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.
    Conlon TJ; Mah CS; Pacak CA; Rucker Henninger MB; Erger KE; Jorgensen ML; Lee CC; Tarantal AF; Byrne BJ
    Hum Gene Ther Clin Dev; 2016 Dec; 27(4):152-159. PubMed ID: 27855487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.
    Elmallah MK; Falk DJ; Nayak S; Federico RA; Sandhu MS; Poirier A; Byrne BJ; Fuller DD
    Mol Ther; 2014 Apr; 22(4):702-12. PubMed ID: 24336173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural deficits contribute to respiratory insufficiency in Pompe disease.
    DeRuisseau LR; Fuller DD; Qiu K; DeRuisseau KC; Donnelly WH; Mah C; Reier PJ; Byrne BJ
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9419-24. PubMed ID: 19474295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
    Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
    Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacious Androgen Hormone Administration in Combination with Adeno-Associated Virus Vector-Mediated Gene Therapy in Female Mice with Pompe Disease.
    Han SO; Gheorghiu D; Chang A; Mapatano SH; Li S; Brooks E; Koeberl D
    Hum Gene Ther; 2022 May; 33(9-10):479-491. PubMed ID: 35081735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
    Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
    Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease.
    Byrne PI; Collins S; Mah CC; Smith B; Conlon T; Martin SD; Corti M; Cleaver B; Islam S; Lawson LA
    Hum Gene Ther Clin Dev; 2014 Sep; 25(3):134-63. PubMed ID: 25238277
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus.
    Rastall DP; Seregin SS; Aldhamen YA; Kaiser LM; Mullins C; Liou A; Ing F; Pereria-Hicks C; Godbehere-Roosa S; Palmer D; Ng P; Amalfitano A
    Gene Ther; 2016 Oct; 23(10):743-752. PubMed ID: 27367841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.
    Wenninger S; Greckl E; Babačić H; Stahl K; Schoser B
    J Neurol; 2019 Jan; 266(1):133-147. PubMed ID: 30430231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.
    Cagin U; Puzzo F; Gomez MJ; Moya-Nilges M; Sellier P; Abad C; Van Wittenberghe L; Daniele N; Guerchet N; Gjata B; Collaud F; Charles S; Sola MS; Boyer O; Krijnse-Locker J; Ronzitti G; Colella P; Mingozzi F
    Mol Ther; 2020 Sep; 28(9):2056-2072. PubMed ID: 32526204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
    Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
    Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.